The combination of serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth

Journal of Urology

Volumn 186, Issue 4, 2011, Pages 1524-1529

  Altavilla, Domenica ^a   Bitto, Alessandra ^a   Polito, Francesca ^b   Irrera, Natasha ^a   Marini, Herbert ^b   Arena, Salvatore ^b   Favilla, Vincenzo ^c   Squadrito, Francesco ^a   Morgia, Giuseppe ^c   Minutoli, Letteria ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

lycopene; prostate; prostatic hyperplasia; selenium; Serenoa

Indexed keywords

CASPASE 9; EPIDERMAL GROWTH FACTOR; LYCOPENE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; SABAL EXTRACT; SELENATE; TESTOSTERONE PROPIONATE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; RAT; SABAL;

ANIMALS; ANTIOXIDANTS; BCL-2-ASSOCIATED X PROTEIN; CAROTENOIDS; CASPASE 9; MALE; ORGAN SIZE; PHYTOTHERAPY; PLANT PREPARATIONS; PROSTATE; PROSTATIC HYPERPLASIA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; SELENIUM; SERENOA; TESTOSTERONE PROPIONATE;

EID: 80052729401     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.05.049     Document Type: Article

References (30)

1. C.G. Roehrborn Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) Med Clin North Am 95 2011 87
2. D.J. Tindall, and R.S. Rittmaster The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer J Urol 179 2008 1235
3. P.J. Hendriksen, N.F. Dits, and K. Kokame Evolution of the androgen receptor pathway during progression of prostate cancer Cancer Res 66 2006 5012
4. C.G. Roehrborn Clinical management of lower urinary tract symptoms with combined medical therapy BJU Int 102 2008 13
5. C.C. Schulman Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment Urology 62 2003 24
6. G. Kramer, D. Mitteregger, and M. Marberger Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51 2007 1202
7. M.S. Lucia, and J.R. Lambert Growth factors in benign prostatic hyperplasia: basic science implications Curr Urol Rep 9 2008 272
8. J. Tacklind, R. MacDonald, and I. Rutks Serenoa repens for benign prostatic hyperplasia Cochrane Database Syst Rev 2 2009 CD001423
9. G. Bonvissuto, L. Minutoli, and G. Morgia Effect of Serenoa repens, lycopene and selenium, on proinflammatory phenotype activation: an "in vitro" and "in vivo" comparison study Urology 77 2011 248.e9
10. G. Morgia, G. Mucciardi, and A. Gal Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study Urol Int 84 2010 400
11. V. Magri, A. Trinchieri, and G. Perletti Activity of Serenoa repens, lycopene and selenium on prostatic disease: evidences and hypotheses Arch Ital Urol Androl 80 2008 65
12. C.M. Yang, Y.T. Yen, and C.S. Huang Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice Mol Nutr Food Res 55 2011 606
13. P. Palozza, M. Colangelo, and R. Simone Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines Carcinogenesis 31 2010 1813
14. Z. Polívková, P. Smerák, and H. Demová Antimutagenic effects of lycopene and tomato purée J Med Food 13 2010 1443
15. K. Lunøe, C. Gabel-Jensen, and S. Strup Investigation of the selenium metabolism in cancer cell lines Metallomics 3 2011 162
16. B.L. Lindshield, N.A. Ford, and K. Canene-Adams Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors PLoS One 5 2010 e10423
17. X. Liu, R. Gao, and Y. Dong Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition BMC Cancer 10 2010 418
18. L. Jiang, K.H. Yang, and J.H. Tian Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: a meta-analysis of randomized controlled trials Nutr Cancer 62 2010 719
19. M.L. Arruzazabala, D. Carbajal, and R. Mas Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on prostate hyperplasia induced with testosterone in intact and castrated rodents Drugs Exp Clin Res 30 2004 227
20. P.T. Daniel Dissecting the pathways to death Leukemia 14 2000 2035
21. D.M. Hockenbery, Z.N. Oltvai, and X.M. Yin Bcl-2 functions in an antioxidant pathway to prevent apoptosis Cell 75 1993 241
22. J.C. Reed Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance Curr Opin Oncol 7 1995 541
23. K. Revelos, C. Petraki, and A. Gregorakis Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy Anticancer Res 25 2005 3123
24. D.R. Green, and J.C. Reed Mitochondria and apoptosis Science 281 1998 1309
25. R.E. Gerstenbluth, A.D. Seftel, and G.T. MacLennan Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation J Urol 167 2002 2267
26. F. Di Silverio, S. Monti, and A. Sciarra Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia Prostate 37 1998 77
27. N. Prenzel, O.M. Fischer, and S. Streit The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer 8 2001 11
28. G. Di Lorenzo, G. Tortora, and F.P. D'Armiento Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin Cancer Res 8 2002 3438
29. M.W. Jackson, J.M. Bentel, and W.D. Tilley Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia J Urol 157 1997 2323
30. C. Ortholan, J. Durivault, and J.M. Hannoun-Levi Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment Eur J Cancer 46 2010 3022